Sanofi Shares Under Pressure Amid Growth Concerns

Sanofi's Lunsekimig shows promise in asthma but fails in atopic dermatitis trial, amplifying investor worries over its pipeline ahead of Dupixent's 2031 patent cliff.

Investors are reassessing the long-term outlook for pharmaceutical giant Sanofi following a mixed set of clinical trial results for one of its key drug candidates. The divergent data has amplified existing worries about the company's growth trajectory as it approaches a significant patent expiration.

A Drug Candidate's Divergent Path

This week, Sanofi presented updated clinical findings for its investigational treatment, Lunsekimig. The outcomes were a study in contrasts. While the drug successfully met its primary endpoints in trials for asthma and chronic rhinosinusitis with nasal polyps, it failed to achieve the main goal in a separate Phase 2 study for atopic dermatitis, known as the Velvet trial.

The market's reaction to this partial success was swift and negative. Within the fiercely competitive dermatology sector, the setback in the atopic dermatitis study was viewed as a disappointment. Sanofi's stock closed Tuesday's session at 80.35 euros, placing it at the bottom of the Euro Stoxx 50 index and registering a weekly decline of 3.56 percent.

Strategic Uncertainty and a Looming Patent Cliff

Financial analysts have offered varied interpretations of the pipeline news. JPMorgan characterized the data as slightly positive but called for greater clarity on the future competitive landscape, maintaining its price target of 95 euros. In contrast, the analysis firm AlphaValue adopted a more cautious stance. It reduced its price target from 112 to 105 euros and, more significantly, slashed its long-term growth forecast for Sanofi from 1.5% to just 0.5%.

This downgrade is directly tied to a major strategic challenge. The company's blockbuster drug, Dupixent, which currently generates approximately 36% of total group revenue, is set to lose patent protection starting in 2031. The inconsistent performance of Lunsekimig has intensified investor concern that Sanofi may not develop adequate successor products swiftly enough to fill the impending revenue gap.

The current share price weakness reflects this fundamental uncertainty. Although a Relative Strength Index (RSI) reading of 31.8 indicates the stock may be nearing oversold territory in the short term, the market is demanding concrete evidence for a sustained recovery. Until management can convincingly outline a pathway to replace future Dupixent sales with new, successful medications, a meaningful re-rating of the stock appears unlikely. The pressure is on for Sanofi to demonstrate robust pipeline execution.